Clinical trials: Disease Exacerbation
COPD
Predicting the Course of Chronic Obstructive Pulmonary Disease (COPD) in Primary Care
Background: COPD is a systemic illness; morbidity and mortality due to this disease are on the increase, and it has great impact on patients' lives. Most COPD patients are managed by general practitioners (GP).
- Trial name
- ICECOLDERIC (NCT00706602)
- Where
- Switzerland
- Volunteers
- 450 people
- Sponsor
- University of Zurich
Asthma
Cessation Versus Continuation of Long-term Mepolizumab in Severe Eosinophilic Asthma Patients
Primary objective of the study is to evaluate whether patients with severe eosinophilic asthma who have received long-term treatment with mepolizumab (at least 3 years) need to maintain treatment with mepolizumab to continue to…
- Trial name
- NCT02555371
- Testing
- Mepolizumab 100mg
- Where
- 73 sites in United States, Argentina and 12 more
- Volunteers
- 306 people
- Sponsor
- GlaxoSmithKline
COPD (Chronic Obstructive Pulmonary Disease)
Evaluation of the Paramedic Evaluation for Acute COPD Exacerbation
Chronic Obstructive Pulmonary Disease (COPD) is a serious lung condition that affects millions of people in the United States. Each year, it leads to about 150,000 deaths, nearly 900,000 emergency room visits, and 700,000…
- Trial name
- PEACE (NCT07072039)
- Testing
- Paramedic Evaluation for acute COPD Exacerbation, Usual Care
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- University of Massachusetts, Worcester
Asthma Acute, Asthma Exacerbation
45th Multicenter Airway Research Collaboration
The study is a randomized controlled trial on the effect of emergency department initiation of Airsupra on acute asthma "recurrence" at 3 months and other related outcomes (acute asthma relapse, asthma control).
- Conditions
- Asthma Acute, Asthma Exacerbation, Asthma, Asthma Control Level
- Trial name
- MARC-45 (NCT07166939)
- Testing
- Airsupra
- Where
- United States
- Volunteers
- 1,860 people
- Sponsor
- Massachusetts General Hospital
COPD Exacerbation
Stratified TreAtment to Reduce Risk in COPD
To evaluate the efficacy of blood-eosinophil directed corticosteroid therapy using near-patient testing, compared to current standard practice during an exacerbation of COPD in a multi-centre randomised placebo controlled trial.
- Trial name
- STARR2 (NCT04458636)
- Testing
- Prednisolone
- Where
- United Kingdom
- Volunteers
- 203 people
- Sponsor
- University of Oxford
COPD (Chronic Obstructive Pulmonary Disease), COPD Exacerbations
The REVIVE Pivotal Study
The goal of this study is to test whether a new treatment called the Ryme Medical Targeted Lung Denervation (TLD) Catheter is safe and effective for people with moderate to severe chronic obstructive pulmonary disease (COPD).
- Conditions
- COPD (Chronic Obstructive Pulmonary Disease), COPD Exacerbations, COPD Patients, COPD Acute Exacerbation
- Trial name
- REVIVE (NCT07361653)
- Testing
- Ryme TLD
- Volunteers
- 300 people
- Sponsor
- Ryme Medical, Inc.
Colitis, Ulcerative, Colitis Ulcerative Exacerbation
Beneficial and Harmful Effects of Azathioprine and Allopurinol Versus Standard Azathioprine Therapy for Patients With Ulcerative Colitis
Azathioprine is considered first line immunomodulatory therapy for patients with ulcerative colitis. Up to 50% are treatment failures or experience adverse events leading to treatment withdrawal.
- Trial name
- NCT03101800
- Testing
- Azathioprine and Allopurinol, Azathioprine
- Where
- Denmark
- Volunteers
- 84 people
- Sponsor
- Hvidovre University Hospital
Asthma
A Study to Determine the Clinical Characteristics, Comorbidities, Treatment Status and Exacerbations of Asthma Patients
This is a prospective cohort study that aims to determine the current demographics, clinical characteristics, comorbidities, treatment status and exacerbations of asthma patients.
- Trial name
- NCT03239431
- Testing
- asthmatic exacerbation
- Where
- Hong Kong
- Volunteers
- 400 people
- Sponsor
- Chinese University of Hong Kong
Cystic Fibrosis
MUCOviscidose EXacerbation Outils Connectés Education Thérapeutique
Early detection of pulmonary exacerbations (PEx) in Cystic Fibrosis (CF) patients is important to quickly trigger treatment and reduce respiratory damage.
- Trial name
- MucoExocet (NCT03304028)
- Testing
- Connected Devices for 3 months, Educationnal Intervention, Connected Devices for 12 months
- Where
- 7 sites in France
- Volunteers
- 36 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Chronic Obstructive Pulmonary Disease, COPD
Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease. Ratio-Study. (BY217/M2-112)
The purpose of this study is to investigate the effect of 500mcg roflumilast vs placebo on exacerbation rate and pulmonary function as well as quality of life in patients with chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT00430729
- Testing
- Roflumilast
- Where
- 14 sites in Australia, Austria and 12 more
- Volunteers
- 1,100 people
- Sponsor
- AstraZeneca
Generalized Myasthenia Gravis (gMG)
Zilucoplan for Severe gMG Exacerbations
This is an open-label, multicenter, interventional phase 3b study in participants with AChR+ gMG and severe exacerbation that require hospitalization. Patients will receive subcutaneous zilucoplan injections daily for 12 weeks.
- Trial name
- NCT07215949
- Testing
- Zilucoplan®
- Where
- 3 sites in United States
- Volunteers
- 15 people
- Sponsor
- Miriam Freimer
Schizophrenia
Dose-response Study to Evaluate Safety, Efficacy, and Pharmacokinetics of PF-00217830 Compared With Placebo in Acute Exacerbation of Schizophrenia
The objective of this study is demonstrate efficacy and a dose-response in the treatment of acute exacerbation of schizophrenia in comparison to placebo.
- Trial name
- NCT00580125
- Testing
- PF-00217830, Aripiprazole
- Where
- 26 sites in United States, India and 2 more
- Volunteers
- 164 people
- Sponsor
- Pfizer
Chronic Obstructive Pulmonary Disease (COPD)
Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (COPD): The HERMES Study (BY217/M2-125)
The aim of the study is to compare the effect of roflumilast on exacerbation rate and pulmonary function in patients with chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT00297115
- Testing
- Roflumilast
- Where
- 287 sites in United States, Canada and 6 more
- Volunteers
- 1,568 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive, Respiratory Tract Diseases
Do the SPPB and 4-metre Gait Speed Predict Hospital Readmission in Patients Hospitalised for Acute Exacerbation if COPD?
This study aims to evaluate simple tests of physical function in hospitalised patients with chronic obstructive pulmonary disease (COPD) and to assess whether they can predict future hospital readmission.
- Conditions
- Pulmonary Disease, Chronic Obstructive, Respiratory Tract Diseases, Lung Diseases, Lung Diseases, Obstructive
- Trial name
- NCT01507415
- Where
- 2 sites in United Kingdom
- Volunteers
- 226 people
- Sponsor
- Royal Brompton & Harefield NHS Foundation Trust
Pulmonary Disease, Chronic Obstructive, COPD Exacerbation
Mechanisms of COPD Exacerbation Recurrence
Chronic obstructive pulmonary disease (COPD) is a common smoking-related lung disease. Patients with COPD are at increased risk of readmission to hospitals within the following 30 days.
- Conditions
- Pulmonary Disease, Chronic Obstructive, COPD Exacerbation, Patient Readmission, Recurrence
- Trial name
- NCT04024735
- Testing
- Spirometry, Forced Oscillation Technique, Step-counter, sputum and blood samples
- Where
- United Kingdom
- Volunteers
- 166 people
- Sponsor
- University College, London
COPD Exacerbation
High-intensity Resistance Training in Post-exacerbation COPD
After a COPD exacerbation, many individuals experience severe weakness in the leg muscles, especially the quadriceps. This weakness can make daily activities difficult and slow down recovery.
- Trial name
- NCT07302425
- Testing
- HIRT, HIET
- Where
- Italy
- Volunteers
- 64 people
- Sponsor
- Istituti Clinici Scientifici Maugeri SpA
Cystic Fibrosis
A Study Comparing Continuous Infusion Antibiotics to Standard Treatment for Lung Infections in Cystic Fibrosis
Cystic fibrosis (CF) is an inherited disorder which results in increased thickness of secretions, especially in the lungs. By adulthood, the majority of patients with CF will have a bacteria living in their lungs, called…
- Trial name
- CISTIC (NCT01667094)
- Testing
- Intermittent, short infusion Ceftazidime, Continuous infusion Ceftazidime, Intermittent, short infusion Meropenem
- Where
- Australia
- Volunteers
- 50 people
- Sponsor
- The Alfred
Chronic Obstructive Pulmonary Disease With Exacerbation
Comparative Effectiveness of Roflumilast and Azithromycin in Reducing Exacerbations in Severe Chronic Obstructive Pulmonary Disease ( COPD ) Patients With Chronic Bronchitis Phenotype
"The study is a randomized controlled trial comparing roflumilast and azithromycin as add-on therapies in 70 patients with severe chronic obstructive pulmonary disease (COPD ) and frequent exacerbations.
- Trial name
- COPD (NCT07795086)
- Testing
- Roflumilast Oral Tablet, Azithromycin 250 mg
- Volunteers
- 70 people
- Sponsor
- Sidra Aziz
Cystic Fibrosis
Early Intervention in Pulmonary Exacerbation in Cystic Fibrosis
This study will be performed at the University of Washington. Forty subjects with Cystic Fibrosis will be enrolled, with 20 randomized into the usual care arm and 20 randomized into the intervention arm.
- Trial name
- NCT00850551
- Testing
- Early Intervention
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- University of Washington
Asthma
PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network Study
The primary objective of this study is to evaluate several interventions given to participants with severe asthma. Interventions are administered in a crossover manner with 16-week treatment periods followed by 8 to 16 week…
- Trial name
- NCT04129931
- Testing
- MCT, Clazakizumab, Broncho-Vaxom
- Where
- 29 sites in United States
- Volunteers
- 950 people
- Sponsor
- University of North Carolina, Chapel Hill
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.